Summary
Axon Enterprise, Inc. (AXON) announced a significant enhancement to its financial flexibility through an Amended and Restated Credit Agreement signed on December 31, 2018. This agreement substantially increases the company's unsecured revolving line of credit from $10.0 million to $50.0 million. This expanded credit facility, with $10 million earmarked for letters of credit, provides Axon with greater resources for operational needs, potential acquisitions, or other strategic initiatives.
Key Highlights
- 1Increased Revolving Credit Facility: The company's unsecured revolving line of credit has been expanded from $10.0 million to $50.0 million.
- 2Letters of Credit Availability: $10 million of the new credit facility is available for the issuance of letters of credit.
- 3Maturity Date: The credit agreement matures on December 31, 2021.
- 4Accordion Feature: The agreement includes an accordion feature allowing for potential expansion of the credit line up to $100 million, subject to certain conditions.
- 5Interest Rate Structure: Advances will bear interest based on LIBOR plus a margin of 1.0% to 1.5%, determined by a pricing grid tied to the Company's Leverage Ratio.
- 6Leverage Covenant: The company must adhere to a maximum Leverage Ratio of no greater than 2.50 to 1.00.
- 7No Initial Borrowings: As of the closing date, no borrowings were outstanding under the new credit agreement.
Frequently Asked Questions
The primary impact for investors is Axon's enhanced financial flexibility. The unsecured revolving credit facility has been significantly increased to $50.0 million, providing the company with more readily available capital for operational needs, growth opportunities, or unexpected expenditures. The potential to expand this facility further up to $100 million also signals confidence in the company's future financial standing.
The new credit agreement increases the revolving line of credit to $50.0 million, with $10 million available for letters of credit. It matures on December 31, 2021, and includes an option to increase the facility up to $100 million. Interest rates are tied to LIBOR plus a margin based on Axon's leverage ratio. Customary covenants and events of default are also included.
No, the filing suggests the opposite. As of the closing date of the agreement, there were no borrowings outstanding under the new credit facility. This indicates that Axon is proactively securing access to capital, likely as a strategic move to support future growth and maintain financial flexibility, rather than addressing an immediate capital shortage.
The Leverage Ratio is a key financial metric defined in the credit agreement, likely representing the ratio of funded debt to earnings before interest, taxes, depreciation, and amortization (EBITDA). The company must maintain this ratio below 2.50 to 1.00. This covenant is important as it demonstrates to lenders Axon's ability to manage its debt obligations relative to its operational profitability and acts as a safeguard for the lenders.